There are 2137 resources available
533MO - Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
Presenter: Nicolas Girard
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1260MO - Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
Presenter: Giuseppe Giaccone
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA58 - ORR in patients receiving nivolumab plus radiotherapy in advanced non-small cell lung cancer: First results from the FORCE trial
Presenter: Farastuk Bozorgmehr
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA59 - First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA
Presenter: Martin Reck
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA60 - ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
Presenter: Mark Socinski
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA61 - First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions
Presenter: Stephen Liu
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1261MO - Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)
Presenter: Gregory Riely
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA62 - Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
Presenter: Helena Yu
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1421MO - Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma
Presenter: Salah-Eddin Al-Batran
Session: Mini Oral - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
1625MO - ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non metastatic extremity high grade osteosarcoma: An Italian Sarcoma Group (ISG) multicentric prospective trial (ISG/OS-2)
Presenter: Emanuela Palmerini
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast